Verastem recently released its latest 10-Q, showing a company that now has a commercial product in the U.S. while still spending heavily on a broader oncology pipeline. The company develops and markets AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have already received systemic therapy. Beyond that marketed product, Verastem is advancing avutometinib and defactinib in additional studies, including RAMP 301, RAMP 201, FRAME and RAMP 205, while also pursuing VS-7375, an oral KRAS G12D inhibitor, through the TARGET-D program.
For the quarter ended March 31, 2026, Verastem reported $18.7 million of product revenue, up from zero a year earlier, as commercial sales began after FDA approval on May 8, 2025. Cost of sales tied to the product was $2.8 million, including manufacturing, royalties and some inventory write-downs, while research and development expense rose 31% to $38.2 million from $29.2 million. Selling, general and administrative expense increased 48% to $22.3 million from $15.0 million, pushing total operating expenses to $63.6 million from $44.2 million.
The company’s operating loss narrowed only slightly, to $44.9 million from $44.2 million, because higher revenue was offset by larger development and commercial spending. Net loss improved to $36.6 million from $52.1 million, helped by a $9.3 million gain from the change in fair value of warrant liability versus a $2.4 million loss a year earlier, and by the absence of a $1.8 million debt extinguishment charge booked in the prior-year quarter. Interest income rose to $1.3 million from $1.0 million, while interest expense increased to $382,000 from $192,000.
Verastem ended March 31, 2026 with $181.7 million in cash, cash equivalents and investments and an accumulated deficit of $1.20 billion. Management said the initiation of TARGET-D 201, TARGET-D 202 and TARGET-D 203 materially increased expected research and development spending, creating substantial doubt about its ability to continue as a going concern within 12 months of the financial statement issuance date. The company said it expects to fund operations through existing cash and investments, possible milestones and royalties under the Secura asset purchase agreement, the note purchase agreement, future product revenue and other financing options, including collaborations, equity offerings or debt. Following these announcements, the company's shares moved -5.32%, and are now trading at a price of $5.69. For the full picture, make sure to review Verastem's 10-Q report.
